Enlivex Therapeutics H1 Research And Development Expenses $10.2M Vs $8.8M YoY
Portfolio Pulse from Benzinga Newsdesk
Enlivex Therapeutics has reported an increase in its H1 research and development expenses to $10.2M, up from $8.8M year-on-year.

September 11, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Enlivex Therapeutics' research and development expenses have increased to $10.2M in H1, up from $8.8M YoY.
The increase in R&D expenses indicates that the company is investing more in its research and development activities. This could potentially lead to new products or improvements in existing ones, which could boost the company's revenues in the future. However, in the short term, this increase in expenses could negatively impact the company's profitability, which could put downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100